SYDNEY–(BUSINESS WIRE)—- $III #AI–Firms in Asia Pacific are replacing legacy finance and human capital management systems with a Workday platform that improves visibility, ISG says.
Author: sHq_LoGiNz
FORT WORTH, Texas–(BUSINESS WIRE)–Distribution Solutions Group, Inc. (NASDAQ: DSGR) (“DSG” or the “Company”), a premier specialty distribution company, today announced the successful closing of its previously announced acquisition of GradeEight Holdings, LLC (“GradeEight”), a multi-brand MRO distribution platform operating through a national network of franchisees under Winzer Corporation (“Winzer”), and retail-facing storefronts under FastServ Supply across Texas and Arkansas. The transactio
西班牙马德里–(BUSINESS WIRE)–(美国商业资讯)– 2026年欧洲肿瘤内科学会（ESMO）年会正于西班牙马德里举行。西达本胺（HBI-8000，爱谱沙®）联合纳武利尤单抗治疗晚期黑色素瘤的全球III期临床主要分析结果（摘要编号LBA54）于优选论文报告专场（Proffered Paper Session）进行口头报告。西达本胺其他多项探索成果也同步亮相大会。 专场报告详情 研究标题： Primary Analysis of HBI-8000-303: A Randomized Phase 3 Trial of Nivolumab plus HBI-8000 or Placebo in Advanced Melanoma 中文标题： HBI-8000-303的主要分析：纳武利尤单抗联合HBI-8000或安慰剂治疗晚期黑色素瘤的随机III期试验 摘要编号： LBA54 核心要点 研究背景：在免疫治疗和靶向治疗的推动下，晚期黑色素瘤患者的预后已得到显著改善。在一项针对PD-(L)1抑制剂初治晚期黑色素瘤患者的1b/2期研究中，口服选择性组蛋白去乙酰化酶（HDAC）抑制剂H
SEOUL, South Korea–(BUSINESS WIRE)– #ADC–AimedBio, a clinical-stage biotech company, announces first patient dosed in Phase I trial of ADC candidate BI 4060107.